Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
O&D-001 in Relapsed or Refractory Multiple Myeloma
NCT07369895Phase 1Recruiting
- Sponsor
- O&D Bio
- Start
- Oct 2025
- Primary completion
- Mar 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of O&D-001 in multiple myeloma (MM), sponsored by O&D Bio. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events and Serious Adverse Events at 6 months. Started Oct 2025; status: recruiting.
02
Drugs
O&D-001
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07369895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07369895.